Literature DB >> 29540265

The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS.

Sherrie L Kelly1, Rowan Martin-Hughes2, Robyn M Stuart3, Xiao F Yap2, David J Kedziora4, Kelsey L Grantham5, S Azfar Hussain2, Iyanoosh Reporter2, Andrew J Shattock6, Laura Grobicki7, Hassan Haghparast-Bidgoli7, Jolene Skordis-Worrall7, Zofia Baranczuk8, Olivia Keiser9, Janne Estill10, Janka Petravic4, Richard T Gray6, Clemens J Benedikt11, Nicole Fraser11, Marelize Gorgens11, David Wilson11, Cliff C Kerr12, David P Wilson4.   

Abstract

BACKGROUND: To move towards ending AIDS by 2030, HIV resources should be allocated cost-effectively. We used the Optima HIV model to estimate how global HIV resources could be retargeted for greatest epidemiological effect and how many additional new infections could be averted by 2030.
METHODS: We collated standard data used in country modelling exercises (including demographic, epidemiological, behavioural, programmatic, and expenditure data) from Jan 1, 2000, to Dec 31, 2015 for 44 countries, capturing 80% of people living with HIV worldwide. These data were used to parameterise separate subnational and national models within the Optima HIV framework. To estimate optimal resource allocation at subnational, national, regional, and global levels, we used an adaptive stochastic descent optimisation algorithm in combination with the epidemic models and cost functions for each programme in each country. Optimal allocation analyses were done with international HIV funds remaining the same to each country and by redistributing these funds between countries.
FINDINGS: Without additional funding, if countries were to optimally allocate their HIV resources from 2016 to 2030, we estimate that an additional 7·4 million (uncertainty range 3·9 million-14·0 million) new infections could be averted, representing a 26% (uncertainty range 13-50%) incidence reduction. Redistribution of international funds between countries could avert a further 1·9 million infections, which represents a 33% (uncertainty range 20-58%) incidence reduction overall. To reduce HIV incidence by 90% relative to 2010, we estimate that more than a three-fold increase of current annual funds will be necessary until 2030. The most common priorities for optimal resource reallocation are to scale up treatment and prevention programmes targeting key populations at greatest risk in each setting. Prioritisation of other HIV programmes depends on the epidemiology and cost-effectiveness of service delivery in each setting as well as resource availability.
INTERPRETATION: Further reductions in global HIV incidence are possible through improved targeting of international and national HIV resources. FUNDING: World Bank and Australian NHMRC.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29540265     DOI: 10.1016/S2352-3018(18)30024-9

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  20 in total

1.  Estimating Costs of the HIV Comprehensive Intervention Using the Spectrum Model - China, 2015-2019.

Authors:  Youran Zhang; Lili Wang; Zhen Jiang; Hongjing Yan; Xiaoxia Liu; Jing Gu; Guoyong Wang; Xiaosong Cheng; Qiyan Leng; Qisui Long; Zimian Liang; Jing Wang; Liang Liang; Yanchao Qiu; Lin Chen; Hang Hong
Journal:  China CDC Wkly       Date:  2022-06-24

2.  "Optima attempts to objectively and pragmatically assist countries meet their targets most efficiently and effectively".

Authors:  David P Wilson; Marelize Gorgens; David J Wilson
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396

3.  Measuring financial risk protection in health benefits packages: scoping review protocol to inform allocative efficiency studies.

Authors:  Gerard Joseph Abou Jaoude; Jolene Skordis-Worrall; Hassan Haghparast-Bidgoli
Journal:  BMJ Open       Date:  2019-05-28       Impact factor: 2.692

4.  Inclusive engagement for health and development or 'political theatre': results from case studies examining mechanisms for country ownership in Global Fund processes in Malawi, Tanzania and Zimbabwe.

Authors:  Russell Armstrong; Arlette Campbell White; Patrick Chinyamuchiko; Steven Chizimbi; Sarah Hamm Rush; Nana K Poku
Journal:  Global Health       Date:  2019-05-07       Impact factor: 4.185

Review 5.  Evolving HIV epidemics: the urgent need to refocus on populations with risk.

Authors:  Tim Brown; Wiwat Peerapatanapokin
Journal:  Curr Opin HIV AIDS       Date:  2019-09       Impact factor: 4.283

Review 6.  The Role of Phylogenetics in Discerning HIV-1 Mixing among Vulnerable Populations and Geographic Regions in Sub-Saharan Africa: A Systematic Review.

Authors:  George M Nduva; Jamirah Nazziwa; Amin S Hassan; Eduard J Sanders; Joakim Esbjörnsson
Journal:  Viruses       Date:  2021-06-19       Impact factor: 5.048

7.  Temporal Variation in One-Time Partnership Rates Among Young Men Who Have Sex With Men and Transgender Women.

Authors:  Patrick Janulis; Steven M Goodreau; Michelle Birkett; Gregory Phillips; Martina Morris; Brian Mustanski; Samuel M Jenness
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771

8.  Diabetes care cascade in Ukraine: an analysis of breakpoints and opportunities for improved diabetes outcomes.

Authors:  Robyn Margaret Stuart; Olga Khan; Romesh Abeysuriya; Tetyana Kryvchun; Viktor Lysak; Alla Bredikhina; Nina Durdykulyieva; Volodymyr Mykhailets; Elvira Kaidashova; Olena Doroshenko; Zara Shubber; David Wilson; Feng Zhao; Nicole Fraser-Hurt
Journal:  BMC Health Serv Res       Date:  2020-05-11       Impact factor: 2.655

9.  The influence of constraints on the efficient allocation of resources for HIV prevention.

Authors:  Isaac J Stopard; Jessica B McGillen; Katharina Hauck; Timothy B Hallett
Journal:  AIDS       Date:  2019-06-01       Impact factor: 4.177

10.  Migration, hotspots, and dispersal of HIV infection in Rakai, Uganda.

Authors:  Mary Kate Grabowski; Justin Lessler; Jeremiah Bazaale; Dorean Nabukalu; Justine Nankinga; Betty Nantume; Joseph Ssekasanvu; Steven J Reynolds; Robert Ssekubugu; Fred Nalugoda; Godfrey Kigozi; Joseph Kagaayi; John S Santelli; Caitlin Kennedy; Maria J Wawer; David Serwadda; Larry W Chang; Ronald H Gray
Journal:  Nat Commun       Date:  2020-02-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.